Business
Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR)
- First rigorous analysis estimates TSC1 and TSC2 definite impact alteration incidence in U.S. as approximately 12,000 advanced cancer patients in 2030 -
About this update from Whitehawk Therapeutics, Inc.
[{"type":"text","content":"- First rigorous analysis estimates TSC1 and TSC2 definite impact alteration incidence in U.S. as approximately 12,000 advanced cancer patients in 2030 - Findings also identify highest frequency of TSC1 alterations in bladder, kidney, and lung squamous cell cancers, while TSC2 alterations have the highest frequency in hepatobiliary, ovarian, and soft tissue sarcomas LOS ANGELES, April 08, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of a poster (#5799) at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 8-13, 2022 in New Orleans, LA. The research that was presented quantifies the type and number of advanced cancer patients with malignant tumors carrying TSC1 or TSC2 alterations. The study, presented by Gunsagar S. Gulati, M.D., Ph.D., Resident Physician at Brigham and Women’s Hospital (BWH) in Boston evaluated the landscape of TSC1 or TSC2 alterations across 31 solid tumors from The Cancer Genome Atlas (TCGA; n ~10,000 patients), AACR GENIE database (Memorial Sloan Kettering (MSK): n ~ 15,000 patients, and Dana Farber Cancer Institute (DFCI): n ~ 5,500 patients) and subsequently estimated the annual incidence of patients with these alterations using the Surveillance, Epidemiology, and End Results Program (SEER) database. The study, which was conducted by additional researchers at BWH, The University of Texas MD Anderson Cancer Center, and Tessellon in Missouri, found that the incidence of advanced cancer patients with TSC1 or TSC2 alterations in 2030 in the U.S. is projected to be approximately 32,000, of which approximately 12,000 patients carry “definite” mutations (frameshift, nonsense, splice-site mutations and deep deletions). TSC1 alterations were most frequent in bladder, kidney, and lung squamous cell cancers, while TSC2 alterations were most frequent in hepatobiliary, ovarian, and soft tissue sarcomas. Neil Desai, Ph.D., Founder, Chief Executive Officer, and President of Aadi, stated, “Consistent with our expectations, the incidence of patients with TSC1 or TSC2 definite impact alterations is significant, and only exceeded by the incidence of actionable mutati...